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Vascular endothelial growth factor (VEGF) and avb3 integrin are key molecules that actively participate
in tumor angiogenesis and metastasis. Some integrin-blocking molecules are currently under clinical
trials for cancer and metastasis treatment. However, the mechanism of action of such inhibitors is not
completely understood. We have previously demonstrated the anti-angiogenic and anti-metastatic
properties of DisBa-01, a recombinant His-tag RGD-disintegrin from Bothrops alternatus snake venom
in some experimental models. DisBa-01 blocks avb3 integrin binding to vitronectin and inhibits integrin-
mediated downstream signaling cascades and cell migration. Here we add some new information on the
mechanism of action of DisBa-01 in the tumor microenvironment. DisBa-01 supports the adhesion of
ﬁbroblasts and MDA-MB-231 breast cancer cells but it inhibits the adhesion of these cells to type I
collagen under ﬂow in high shear conditions, as a simulation of the blood stream. DisBa-01 does not
affect the release of VEGF by ﬁbroblasts or breast cancer cells but it strongly decreases the expression of
VEGF mRNA and of its receptors, vascular endothelial growth factor receptors 1 and 2 (VEGFR1 and
VEGFR2) in endothelial cells. DisBa-01 at nanomolar concentrations also modulates metalloprotease 2
(MMP-2) and 9 (MMP-9) activity, the latter being decreased in ﬁbroblasts and increased in MDA-MB-231
cells. In conclusion, these results demonstrate that avb3 integrin inhibitors may induce distinct effects in
the cells of the tumor microenvironment, resulting in blockade of angiogenesis by impairing of VEGF
signaling and in inhibition of tumor cell motility.
 2012 Elsevier Masson SAS. Open access under the Elsevier OA license.1. Introduction
Metastasis is the primary cause of mortality for most cancer
patients. In order to metastasize, cancer cells must achieve new
abilities such as an invasive phenotype. Complex interactions
between cancer cells and the tumormicroenvironment mediate the
main steps of the metastatic cascade that involves migration at the
primary site, intravasation into lymphatic vessels or the blood
stream, where they must survive from the immune system attack,
arrest and extravasation to a new site. Either at the primary tumor
or at the distant site, cancer cells interact with the components of
the tumor microenvironment such as stromal cells, the endothe-
lium and extracellular matrix components. It is well established
that these interactions may facilitate metastatic growth and tissue401.
e-Araujo).
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nder the Elsevier OA license.selectivity. Most metastatic lesions do not respond to conventional
cancer treatments for primary tumors and the development of
metastatic lesions signals for a poor diagnosis. Therefore, a better
understanding of the metastatic process may lead to improved
therapies for cancer patients [1].
The contribution of stromal ﬁbroblasts for the development of
metastasis has been previously demonstrated [2e4]. Fibroblast
stimulation by breast tumor cells results in a proinvasive and
prometastatic phenotype with altered expression of matrix met-
alloprotease (MMP) activity via upregulation of key cytokine
expression [2e4]. It has been recently reported that metastatic
prostate cancer cells irreversibly activated normal ﬁbroblasts to
tumor-associated ﬁbroblasts (TAFs) with subsequent reduced
expression of ECM components, increased expression of MT1-MMP
and enhanced motility [5].
The presence of hypoxia pockets in the tumor mass has been
described as one of the major factors for the development of
metastasis. In hypoxic conditions, tumor cells respond not only to
paracrine signaling but also autocrine signaling to angiogenic
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VEGF autocrine signaling in tumor cells induced by hypoxia leads to
the activation of the PI3-kinase signaling pathway resulting in
decreased apoptosis and stimulation of breast cancer cell migration
toward a chemo attractant gradient [6e8]. VEGF binds to and
activates three types of tyrosine kinase receptors, VEGFR1 (Flt-1)
[8], VEGFR2 (KDR/Flk-1) and VEGFR3 [6,8e11], and several co-
receptors, triggering intracellular signaling pathways that result
in cell migration, survival, and proliferation of endothelial cells.
Negative regulation is mostly due to a soluble VEGFR1 variant that
clears VEGF therefore preventing its binding to VEGFR2 [12]. VEGF
receptors have also been described in tumor cells [6,9]. Thus, VEGF-
targeted therapy has become an important alternative for cancer
treatment and a number of molecules have been submitted to
clinical trials including anti-VEGF antibodies [13]. However, its
effectiveness has a very short-life and many patients do not
respond to VEGF-targeted therapy, while others develop drug
resistance mechanisms and in some cases with increased number
of metastatic foci [14,15]. Therefore, a better understanding of the
tumor microenvironment and search for new targets are relevant
issues.
In most steps of the metastatic cascade, changes in tumor cell
adhesion to stromal cells and to the extracellular matrix (ECM) as
well as proteolytic degradation of ECM byMMPs are needed for cell
invasion. Tumor cell adhesion to ECM is mediated by integrins,
heterodimeric receptors of ECM components [16]. Integrins are
composed by 1 of 18 a and 1 of 8 b chains of transmembrane
proteins that bind to speciﬁc proteins in the ECM. Ligand binding to
integrins switches the receptor from an inactive form to an active
state, which triggers speciﬁc intracellular signaling cascades [17].
There is accumulated evidence that integrins play a key role in
cancer cell proliferation, invasion and apoptosis [18,19]. The a6b4
integrin, a key laminin receptor in adhesion structures such as
hemidesmosomes, induces tumor cell migration by activating PI3k/
Akt pathway [9]. The vitronectin receptor, avb3 integrin, is highly
expressed in endothelial cells of angiogenic vessels [20]. The avb3
integrin is also very important in the process of intravasation and
extravasation of tumor cells [21], and is strongly involved in the
malignant spread of several tumor cell types such as breast and
prostate carcinoma [22]. Blocking avb3 integrin is therefore
expected to have some impact in cancer therapy. A few integrin
blockers have entered in clinical trials with encouraging results
[16]. Most ligands for avb3 and aIIbb3 integrins bind to the
receptors by the adhesive motif arginine-glycine-aspartic acid
(RGD) [23]. For instance, the dual blocking of avb3 and avb5
integrins for inhibition of both angiogenesis and invasion was the
basis of cilengitide design [24]. Cilengitide was demonstrated to
induce endothelial and glioma cell apoptosis by inhibition of the
focal adhesion kinase (FAK) pathway [25].
Previous studies have demonstrated that metastasis is facili-
tated by platelet adhesion to tumor cells, forming coaggregates
and contributing to the arrest at the vasculature [26]. Convincing
evidence for the relevance of platelets in the metastatic process is
the reduced number of metastasis in thrombocytopenic mice
relative to normal animals [26]. Previous studies demonstrated
that tumor cells use the avb3 integrin to bind platelet aIIbb3
integrin via cross-linking plasma protein ligands [27]. However,
antagonists of both platelet integrin receptors only partially block
tumor cell adhesion [26]. These results demonstrated that the
search for new molecules with more speciﬁc anti-integrin activity
is necessary.
Disintegrins comprise a family of nonenzymatic, low-molecular-
weight, cystein-rich peptides from snake venom that speciﬁcally
and potently inhibit integrin functions. Several disintegrins have
demonstrated their anti-cancer properties [28,29]. Contortrostatin,salmosin, accutin or rhodostomin were described with anti-
angiogenic and anti-metastatic activities [30e32]. Many dis-
integrins contain the RGD or the KGD adhesive motif sequence
which acts as a potent antagonist of b1 and b3 integrins, in
particular, a5b1, aIIbb3 and avb3 integrins [33]. However, KTS/RTS-
disintegrins that bind speciﬁcally to a1b1 integrin were recently
demonstrated to have anti-angiogenic properties [34e36].
We have previously reported that DisBa-01, a recombinant His-
tag fusion RGD-disintegrin from Bothrops alternatus snake venom,
inhibits both angiogenesis and lung metastasis in nude mice [21].
DisBa-01 is a high-afﬁnity avb3 and aIIbb3-integrin binding protein
with strong anti-platelet and anti-thrombotic effects [37]. Recently,
it has been demonstrated that DisBa-01 also inhibits tumor cell
migration in vitro [38]. Here we show that DisBa-01 also decreased
the expression of VEGF and its receptors in endothelial cells, but not
in ﬁbroblasts or tumor cells. In addition, this disintegrin modulates
MMP-2 and -9 activities. As far as we know, this is the ﬁrst report of
such activities for this type of integrin blockers. These results add
some new light on the understanding of the role of avb3 integrin
antagonism on the tumor microenvironment.
2. Experimental procedures
2.1. DisBa-01 expression, puriﬁcation and characterization
Since the native DisBa-01 disintegrin could not be puriﬁed from
the venom due to very low yields in protein preparations,
recombinant DisBa-01 was produced from a cDNA venom gland
library of B. alternatus [21]. The coding region corresponds to
a medium disintegrin (78 amino acid residues) with an RGD
adhesive motif (GenBank accession AY259516). Expression and
puriﬁcation of the recombinant His-tag protein were performed as
previously described [21]. N-terminal sequencing conﬁrmed the
expected sequence of the 12 kDa fusion protein which was then
used in all biological assays. Molecular modeling suggested that the
fusion His-tag peptide was not involved in integrin binding and
therefore its proteolytic removal could not be needed [21].
2.2. Cell lines and culture
Human Fibroblasts were purchased from the Cell Bank of Rio
de Janeiro (Brazil) where they were certiﬁed by short tandem
repeat (STR) analysis. Human breast tumor cell line (MDA-MB-
231) was from ATCC. Both cell lines were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM, Vitrocell, Campinas; SP; Brazil)
supplemented with 10% (v/v) fetal bovine serum (FBS). Micro-
vascular endothelial HMEC-1 was cultured in MCDB-131 (GIBCO)
with 10% FBS. All cell lines were cultured in the presence of
penicillin (100 IU/ml), streptomycin (100 mg/ml) and L-glutamine
(2 mM), in a humidiﬁed environment with 5% CO2 at 37 C. For all
cell assays, the cells were harvested with 0.25% trypsin-0.1% EDTA
solution.
2.3. Flow cytometry analysis
The integrin content of the cells was determined using speciﬁc
anti-integrin antibody by ﬂow cytometry. Brief, 1  106 cells were
incubated with 1 mg of anti-integrin at 4 C for 30 min. After, the
cells were washed with PBS and centrifuged at 4 C, for 10 min at
150  g. Then, 0.5 mg of FITC-IgG was added to each sample and
incubated for 30 min at 4 C in the dark. In the end of this time, the
cells were washed again with PBS, centrifuged and the cells were
immediately analysed with FACsCalibur ﬂow cytometer (BD
Bioscience).
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For the static adhesion assay, a 96-well microplate was coated
overnightwith collagen type I, III or IV (1mg/well) inacetic acid (0.1%),
ﬁbronectin (1 mg/well) or the disintegrin (0.1; 1; 10 mg/well) and then
blocked with 1% BSA. Cells (5  104 cells/well) in serum-free DMEM
medium were added to the wells and allowed to adhere to the
substrate during30min at 37 C.After, theunbound cellswere gently
removed and the remaining cells were ﬁxed and stained with 0.5%
crystal violet for 30min. Cellswere thenwashed and lysed by 1% SDS
for 30 min and the absorbance was read at 540 nm. Untreated cells
adhered to the collagen type I and to BSAwere considered as positive
(100%) andnegative control, respectively. A syntheticHis-tagpeptide
(Sigma, USA) was also used as a control. The adhesion assays under
ﬂow were made as previously described [39,40]. Brieﬂy, tumor cells
(107cells/ml) were labeled with cell tracker red CPMTX (Invitrogen)
for 30minand incubatedwithdifferent concentrationsofDisBa-01at
37 C.Whole bloodobtained fromconsentinghealthy humandonors
was anticoagulated with heparin (13 IU/ml) and centrifuged for
20 min at 200  g to obtain platelet-rich plasma (PRP) which was
then labeledwith 5 mg/ml cell trace calcein greenAM (Invitrogen) for
30 min at 37 C. PRP was mixed with the remaining red blood cells
(1:1.5, v/v) and furthermixedwith disintegrin-treated tumor labeled
cells (1:10, v/v). The cover slips coated with collagen I (2.5 mg/ml)
were placed into the chamber and blood containing labeled tumor
cells was perfused through the chamber for 10 min at 1500 s1 at
a constant blood ﬂow rate of 10 mL/min using a peristaltic pump.
After, the cover slips were washed in PBS for 5 min and ﬁfteen
different ﬁelds were captured using the software Scion Visiocapture
Image Acquisition Application on an epiﬂuorescent microscope
(Nikon Eclipse TE 300) coupled to a photo machine. Fluorescent
adhered platelets and cells in each ﬁeld were differentially counted
using the software Image J. Results are expressed as thepercentage of
adhered cells compared to the control without the disintegrin.
2.5. Isolation of total RNA and synthesis of cDNA
Cells in culturemedium(DMEMorMCDB-131) plus 10%FBSwere
incubated in 6 cm dishes (Corning) coated with collagen type I
(1 mg/ml) in medium for 90min at 37 C and 5% CO2. The cells were
then incubated with 0, 1, 10 or 1000 nM DisBa-01. After time incu-
bationof 4, 24, 48 and72h, culturemediumwas removedand stored
at80 C for immunological assays.Cellswere lysedwith coldTRIzol
Reagent (Invitrogen) according to the manufacture’s protocol for
total RNA isolation. RNA concentrations were determined by spec-
trophotometry at 260 nm and RNA integrity was veriﬁed by
ethidium bromide staining on a 1% agarose-formaldehyde gel. Total
RNA was reverse transcribed into cDNA using the M-MLV Reverse
Transcriptase (Promega). cDNAwas stored at 20 C until use.
2.6. Real-time PCR
VEGF, VEGFR1 and VEGFR2 mRNA levels were quantiﬁed by
real-time using the ABI SYBR Green PCR Master Mix (Applied
Biosystems, Fosters City, CA). For VEGFR1 and VEGFR2, the PCR
conditions were the same as previously described (29). The primer
sequences for the analysis of VEGF expression were: forward 50-
CACATTGTTGGAAGAAGCAGCCCA; reverse 50- ACTCACACACACA-
CAACCAGGTCT, and the PCR conditions were: 95 C for 10 min, 40
cycles at 95 C for 15 s, 60 C for 15 s and 72 C for 20 s.
2.7. VEGF enzyme-linked immunoassay
The conditionedmedium of treated and untreated (control) cells
was used for analysis of VEGF expression by ELISA. The assays wereperformed using the kit Quantikine immunoassay for human VEGF
(R&D Systems, Minneaopolis, MN) according to the manufacturer’s
instructions.
2.8. Gelatin zymography
MMP activity was analyzed by the gelatin zymography on
a wound healing assay. Cells (2  105) were seeded in 12 well-
plates, grown at 37 C until conﬂuency and scratched with
a 200 ml plastic tip. Conﬂuent monolayers were washed once with
the appropriate medium to remove cell debris, and medium
without serum and with different DisBa-01 concentrations was
added to the wells. After the treatment, culture medium was
collected, centrifuged at 10,000  g for 5 min at 4 C and incubated
with sample buffer without b-mercaptoethanol. The samples were
resolved at 4 C in a 10% polyacrylamide gel containing 0.1% gelatin.
The gel was washed 2 times with 2.5% Triton X-100 and incubated
at 37 C during 16e22 h in 50 mM Tris buffer pH 8.0, 5 mM CaCl2,
0.02% NaN3 and 10 mM ZnCl2. After staining with Commassie Blue
R-250 and destaining with acetic acid:methanol:water (1:4:5), the
clear bands were quantiﬁed by densitometry using the Gene Tool
version 3.06 software (Syngene, Cambridge, UK).
2.9. Statistical analysis
Each experiment was repeated three times and mean and
standard error were calculated. The results were compared statis-
tically using one-way analysis of variance (ANOVA) and Dunnett’s
statistical test was used when p level were *p < 0.05.
3. Results
3.1. Integrin expression by human ﬁbroblasts and MDA-MB-231
cells
To study the role of DisBa-01 in interfering on avb3 integrin-
mediated cell adhesion, we have ﬁrst analyzed by ﬂow cytometry
the content of some major integrins in the cell types studied.
Human ﬁbroblasts express avb3 and avb5 as well as a6, av and b1
but not a2. Similar results were observed for MDA-MB-231 cells but
these cells express high levels of a2 (Supplementary material 1).
The human microvascular endothelial cell line-1 (HMEC-1) was
reported to express high levels of avb3 [38]. Therefore all the cell
lines were considered good models to investigate the role of a avb3
integrin inhibitor of tumor cell adhesion to ECM.
3.2. DisBa-01 acts like a matrix protein for ﬁbroblasts and tumor
cells
The cells are able to adhere to different ECM proteins by
recognizing adhesive sequences through cellular receptors, such as
integrins. We demonstrate here that DisBa-01 was able to support
the adhesion of ﬁbroblasts and MDA-MB-231 cells similar to
collagen and ﬁbronectin (Fig. 1AeB, respectively). DisBa-01 was
effective in supporting close to maximum ﬁbroblast adhesion with
the lowest amount (0.1 mg/well). A control synthetic His-tag
peptide was ineffective in supporting cell adhesion.
3.3. DisBa-01 affects tumor cell adhesion under ﬂow conditions
We have previously demonstrated that DisBa-01 dose-
dependently inhibited the static adhesion of B16F10 melanoma
cells and of HMEC-1 to vitronectin, with IC50 of 225 nM and
555 nM, respectively [21]. Here we have tested the effect of this
disintegrin in inhibiting the adhesion of MDA-MB-231 cell line
Fig. 2. Inhibition of MDA-MB-231 tumor cell and platelet adhesion to collagen type I
by DisBa-01 under ﬂow conditions. CPMTX-labeled cells (107 cells/ml) were incubated
30 min with DisBa-01 (10, 100, 1000 nM) or PBS (control) and added to whole blood,
prepared in 1:5 dilution with calcein labeled-PRP. The mixture of MDA-MB-231 cells
and blood was perfused (1500 sec1) for 10 min on collagen type I-coated cover slips,
in a perfusion chamber. Tumor cell (A) and platelet (B) adhesion were measured by the
analysis of images taken from ﬁfteen random ﬁelds on each cover slip using the
software Image J. Results are the mean  standard error of three independent
experiments. Statistical analysis was done using Dunnett’s test (*p < 0.05 and
**p < 0.01).
Fig. 1. DisBa-01 acts like a matrix protein for ﬁbroblasts and tumor cells. DisBa-01
supports the adhesion of human ﬁbroblasts (A) and MDA-MB-231 breast tumor cells
(B). Ninety six-well plates were coated with denatured collagen I, III, IV (1 mg/well),
ﬁbronectin (Fn, 1 mg/well), DisBa-01 (0.1; 1; 10 g/well) and His-tag peptide (0.1 and 1.0
mg/well) overnight at 4 C. After blocking with 1% BSA, cells (1  105cells/well) were
seeded in the wells and allowed to adhere for 30 min. Cells were then ﬁxed, staining
with crystal violet and the plate was read at 540 nm. Results are expressed as
percentage of control (considered as 100% attachment) of three independent experi-
ments (**p < 0.01). BSA was used as negative control.
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considered to simulate the human arterial shear rate [29]. We
observed that DisBa-01 strongly inhibited the adhesion of MDA-
MB-231 cells to collagen type I at 100 and 1000 nM concentra-
tions (90% and 64%, respectively) compared with the control
(Fig. 2A). In addition, the adhesion of activated platelets to collagen
I was inhibited only by 10 nM DisBa-01 (33.75%  3.93%) con-
ﬁrming its speciﬁcity for av integrins (Fig. 2B).
3.4. DisBa-01 decreases VEGF expression in HMEC but not in
ﬁbroblasts or MDA-MB-231 cells
Since it was previously demonstrated that ALT-C, an ECD-
disintegrin, Cys-rich protein from B. alternatus venom induced
VEGF expression in ﬁbroblasts [41], we have checked if DisBa-01, an
RGD disintegrin could also induce the same effect. We observed
here that VEGF gene expression levels in human ﬁbroblasts were
not signiﬁcantly altered independently of the incubation time
(4e72 h) and concentration of DisBa-01 (1, 10, 100 and 1000 nM)(Fig. 3A). A signiﬁcant increasing effect was observed only after 24 h
of 1000 nM DisBa-01 treatment. However, DisBa-01 strongly
decreased VEGF mRNA expression in HMEC in all times and tested
concentrations (Fig. 3B). Interestingly, MDA-MB-231 cells also
expressed signiﬁcant levels of VEGF mRNA that were not affected
by the disintegrin with the only exception of 1000 nM of DisBa-01
treatment after 72 h (Fig. 3C).
Surprisingly, VEGF protein levels were signiﬁcantly increased
after 48 and 72 h of 10 and 1000 nM DisBa-01 treatment in the
conditioned medium of ﬁbroblast cultures as detected by ELISA
(Fig. 4A). Since the culture medium was not replaced by fresh
medium during the incubation period, these results could indicate
VEGF accumulation in the conditioned medium. In that case, the
same observation should also be made in the controls. However,
increase in VEGF levels in the conditioned medium of DisBa-01-
treated cells were above the controls thus reﬂecting an effect
induced by the disintegrin.
In agreement with the gene expression results, VEGF protein
levels were not signiﬁcantly modiﬁed in disintegrin-treated MDA-
MB-231 cells (Fig. 4B). It was also observed that these cells express
Fig. 4. DisBa-01 increases VEGF protein expression in ﬁbroblasts. ELISA assays for
VEGF detection were performed using the Quantikine immunoassay kit for human
VEGF in the conditioned medium of (A) Human ﬁbroblasts (HF) or (B) MDA-MB-231
cells incubated with the indicated disintegrin concentrations. Results are repre-
sented as the percentage from the control (100%) as the mean  SEM of three inde-
pendent experiments. In (C), the absolute VEGF levels produced by the two types of
cells are compared. The p value was determined using the using Dunnett’s test
(*p < 0.05; **p < 0.01).
Fig. 3. DisBa-01 modulates VEGF mRNA expression. The levels of VEGF mRNA of DisBa-
01-treated human ﬁbroblasts (A), HMEC (B) and MDA-MB-231 cells (C) were analyzed
by qPCR. Cells were plated on collagen I-coated wells, incubated with the indicated
concentrations of DisBa-01 at several times and then lysed for RNA extraction. The
relative levels of VEGF mRNA were normalized to those of b-actin mRNA compared
with the non-treated control. Results are mean  SEM of three independent experi-
ments. The p value was determined using the using Dunnett’s test (*p < 0.05;
**p < 0.01).
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DisBa-01 did not affect the number of the viable ﬁbroblasts and
MDA-MB-231 cells at the tested concentrations up to 72 h (not
shown). However, the viability of HMEC cells was reported to be
decreased by DisBa-01 at about 42% by concentrations ranging from
5 to 100 nM [21].
3.5. DisBa-01 inhibits the expression of VEGFR1 and VEGFR2 in
HMEC-1 cells
The expression of VEGF receptors in endothelial cells was not
signiﬁcantly altered by ALT-C, an ECD-disintegrin-like, Cys-rich
protein as previously demonstrated by our group [29]. However, we
show here that DisBa-01 (1e100 nM) strongly downregulates
VEGFR1 (Fig. 5A) and VEGFR2 (Fig. 5B) gene expression in HMEC
cells, and this effect was more pronounced with 10 nM DisBa-01.
Similar results were found for cells treated with 100 nM but not
with 1 nM of DisBa-01.3.6. DisBa-01 modulates MMP-2 and MMP-9 activity
We tested next if DisBa-01 could affect MMP activity, which is
considered to be relevant for angiogenesis and cell migration. For
that, the conditioned medium from DisBa-01-treated cells after
a wound healing assay was analyzed in gelatin zymography.
Interestingly, MMP-2 activity was strongly decreased in ﬁbroblast
conditioned medium (Fig. 6A) and this effect was concentration-
dependent in an inverse way, with the highest inhibition induced
by the lowest dose. MMP-9 activity was observed only in the
controls suggesting that it was also inhibited by the disintegrin (not
Fig. 6. Effects of DisBa-01 over MMP-2 and MMP-9 activities in conditioned media
from ﬁbroblast and MDA-MB-231 cultures, respectively. Fibroblasts (upper panel) and
MDA-MB-231 cells (lower panel) were treated with the indicated concentrations of
DisBa-01 for 24 h in a wound healing assay, and the supernatants subjected to gelatin
zymography. Medium without serum from non-treated cells was used as positive
control. Zymograms are representative of a single experiment in triplicate. Each bar
represents the percentage of MMP activity (*p < 0.05; **p < 0.01; ***p < 0.001).
Fig. 5. DisBa-01 inhibits VEGF receptor expression in HMEC-1. Gene expression of
VEGFR1 (A) and VEGFR2 (B) In HMEC-I cells was dose-dependently inhibited by DisBa-
01. Cells were incubated with different concentration of DisBa-01 for several incuba-
tion times (4, 24, 48 and 72 h). RNA was reversed transcribed into cDNA and used in
a real-time PCR with VEGFR1 and VEGFR2 primers. Data are mean  SEM of three
independent experiments. The p value was determined using the Dunnett’s test.
(*p < 0.05; **p < 0.01).
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231 cells which expressed increased MMP-9 activity levels in the
presence of DisBa-01 but MMP-2 was not detected (Fig. 6B).
4. Discussion
Metastatic dissemination depends on a cascade of integrin-
mediated contacts between the tumor and stromal cells as well
as the tumor and the extracellular matrix. Integrin signaling
through avb3 plays a critical role in endothelial cell proliferation
and angiogenesis [42] and in tumor cells can promote migration
andmetastasis [43]. Therefore, blocking avb3 integrin functionmay
be interesting to target several steps of the metastatic cascade and
the tumor microenvironment. We have previously demonstrated
that DisBa-01, an RGD-disintegrin that inhibits avb3 integrin, has
anti-angiogenic and anti-metastatic properties [21]. Here we
present new ﬁndings regarding the action of this protein that helps
to understand its mechanism of action on the tumor
microenvironment.
We have chosen three cell types to study DisBa-01 effects on
a tumor microenvironment: Fibroblasts (stromal cells), endothelial
cells (HMEC), and a tumor cell line from human breast cancer
(MDA-MB-231) in agreement with our previous studies [21]. All
studied cell lines express signiﬁcant levels of avb3 integrin that
explains the ability of DisBa-01 to support cell adhesion. However,
inhibition of cell adhesion studies showed that this protein does
not affect ﬁbroblast and MDA-MB-231 cell binding to collagen I, II,
IV, ﬁbronectin, laminin, thrombospondin, and matrigel [21]. These
results suggest that DisBa-01 acts preferably through binding to
avb3 integrin. Negative adhesion results obtained with a synthetic
His-tag peptide conﬁrm our previous molecular modeling data [21]
that the fusion peptide does not interfere with the biological
activity of DisBa-01.In the present paper we show that DisBa-01 also inhibits (90%)
the adhesion of MDA-MB-231 cells to collagen I under ﬂow
conditions in the presence of blood and platelets. Collagen type I
plays a critical role in initiating angiogenesis by binding to endo-
thelial cells after basement membrane degradation [44]. The avb3
integrin is a canonical vitronectin receptor but it also binds to
collagen I and loss of b1 integrin expression has been reported to
activate avb3 integrin to become functionally dominant and to
induce collagen synthesis [45,46]. Therefore, inhibition of tumor
cell binding to collagen I may be helpful in inhibiting not only
metastasis but also angiogenesis. Interestingly, the lowest
concentration of DisBa-01 induces the more pronounced effect,
a characteristic that is also observed for other assays. RGD-binding
integrins are known to produce bell-shaped curves where low
doses (nanomolar concentrations) may stimulate angiogenesis and
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angiogenesis [47]. There are several examples in the literature of
compounds that act as pro-angiogenics at low concentrations and
anti-angiogenics at higher concentrations such as bortezomib [48],
RGD-mimetic integrin inhibitors [49,50], and TGF-b1 [51] but the
mechanism underlying these effects is poorly understood. This
bell-shaped effect has been suggested as a factor responsible for
resistance to angiogenesis inhibitor treatment [47]. Importantly,
nanomolar concentrations of avb3/avb5eintegrin inhibitors
induced the recycling of both avb3eintegrin and VEGFR2 sug-
gesting an interplay between these receptors [49].
On the other hand, DisBa-01 does not inhibit platelet adhesion
to collagen I in concentrations that inhibit tumor cell adhesion,
with the exception of 10 nM concentration, despite our previous
report of anti-platelet and anti-thrombotic activities of this protein
[37]. These results are probably due to the fact that DisBa-01 does
not affect collagen binding to platelets which is mediatedmostly by
a2b1 integrin and GPVI protein [52]. The ways that platelets
cooperate in tumor cell dissemination is well described in the
literature [53]. Platelets adhere to tumor cells to form coaggregates
that protect them from the cytotoxicity of natural killer cells and
also help tumor cell extravasation to the metastatic niche. Also,
platelets are stores of pro-angiogenic factors that help tumor
invasion and growth. Therefore, inhibition of platelet adhesion
could help in anti-metastatic therapy. However, Gomes et al., [26],
using a similar ﬂow model, demonstrated that the adhesion of
MDA-MB-231 cells to collagen I was only partially (45%) inhibited
by two different non-peptide antagonists (lamiﬁban and SB-
273005) of platelet aIIbb3 and avb3 integrin, respectively [26].
Our results showed that DisBa-01 may represent a better option for
blocking tumor cell adhesion to collagen since it was more effec-
tive, inhibiting approximately 90% of MDA-MB-231 cell adhesion.
DisBa-01 represents a His-tag fusion peptide and despite its
signiﬁcant inhibitory activity, it may produce even stronger effects
if cleaved off from the fusion peptide but this possibility remains to
be determined.
We have previously demonstrated that DisBa-01 inhibits bFGF-
induced angiogenesis in athymic nudemice using thematrigel plug
assay but themechanism of this inhibitionwas not known. Here we
show that DisBa-01 strongly inhibits the expression of VEGF and its
receptors in endothelial cells and these effects are probably medi-
ated by avb3 integrin inhibition. However, the contribution of other
RGD-binding integrins such as avb5, avb6 and avb8 has to be
considered but remains to be determined. Since DisBa-01
decreased endothelial cell viability, it is possible that the decrease
in VEGF levels could be due to endothelial cell death. However, we
measured only the soluble fraction of VEGF. It is possible that
a fraction of VEGF remains associated with the cells as it has been
demonstrated for cells supporting autocrine VEGF signaling [54].
Contrastingly, VEGF protein levels in the conditionedmedium of
ﬁbroblasts culture were increased in the presence of DisBa-01.
Apparently, both ﬁbroblasts and MDA-MB-231 cells express VEGF
constitutively, although the expression level is much higher for the
tumor cells. More importantly, blocking avb3 integrin did not
interfere with VEGF expression in the tumor cells as it did in
endothelial cells thus suggesting that distinct pathways must be
involved in growth factor synthesis in the two types of cells. It has
been recently demonstrated that endothelial FAK deletion in mice
inhibited tumor growth and tumor angiogenesis as well as VEGF-
induced angiogenesis [55] conﬁrming the strong correlation
between angiogenesis and integrin-mediated pathways. Recently,
a cross-talk between endothelial cells and pericytes has been
demonstrated [54]. Pericytes recruited by endothelial cells secrete
vitronectin which through av integrin- and NF-kB- mediated
signaling pathway results in upregulation of VEGF by endothelialcells. These data are in agreement with the results of the present
study since the blockade of avb3 integrin by DisBa-01 inhibits VEGF
protein expression in HMEC.
DisBa-01 also downregulates the expression of VEGFR1 and 2 in
endothelial cells, in addition to the decrease in VEGF protein
expression. VEGFR2 is considered the key mediator of VEGF-
induced angiogenesis [56] and therefore its down regulation
decreases the angiogenic response. However, a compensatory
angiogenic signaling pathway involving the ﬁbroblast growth
factor (FGF) was described as a resistance mechanism to VEGF-
targeted therapies for cancer treatment [57,58]. In addition, it was
reported that VEGF deletion in myeloid cells accelerates tumori-
genesis [59]. Therefore, avb3 integrin-targeted therapy may be an
alternative of anti-angiogenic treatment; however, the develop-
ment of resistance remains to be studied. Unexpectedly, DisBa-01
also affected the expression of VEGF receptors in ﬁbroblast and
MDA-MB-231 cells. Recent work has provided strong evidence that
VEGFR expression is not restricted to endothelial cells but it can
also be detected in other breast cancer cells [60] and in thyroid
follicular cells [61].
Tumor cell migration is a hallmark of metastasis spreading.
Migration is an integrin-mediated process that involves focal
adhesion kinase (FAK) activation and phosphorylation, which,
along with the recruitment of a set of accessory proteins, results in
the activation of the mitogen-associated protein kinase (MAPK)
pathway [62]. Blocking integrin and FAK signaling therefore results
in inhibition of cell migration. We have previously demonstrated
that DisBa-01 strongly inhibits FAK phosphorylation and down-
stream signaling in platelets [37] and also inhibits the migration of
human ﬁbroblasts, prostate cancer cells (DU-145) and MDA-MB-
231 cells toward conditioned medium in similar concentrations to
the ones used in the present study [38].
ECM degradation by MMPs is crucial in order to allow cells to
migrate. A close association between MMP-2 and avb3 integrin has
been suggested since both MMP-2 and MMP-9 localize to the
membrane by binding to avb3 integrin and CD44, respectively [63].
Here we show that inhibition of avb3 (and perhaps a5b1) integrin
by DisBa-01 signiﬁcantly inhibits MMP-2 activity of ﬁbroblasts
which certainly contributes to a decreased migratory ability.
However, MMP-2 activity of MDA-MB-231 cells was not affected by
DisBa-01.
Contrastingly, DisBa-01 stimulates MMP-9 activity in MDA-MB-
231 cells which could also contribute to its anti-angiogenic effect as
we have previously demonstrated [21]. MMP-9 has been associated
to favorable diagnosis in some cases of breast and liver cancer,
probably due to its ability to generate endogenous angiogenesis
inhibitors such as angiostatin from collagen IV [64]. Interestingly,
contortrostatin, a homodimeric RGD disintegrin was reported to
inhibit the invasion of glioma cells through matrigel without
affecting MMP activity [65]. If these distinct effects are due to the
differences in disintegrin structure, cell types or assays remains to
be determined.
In summary, we show here that the blockade of avb3 integrin by
DisBa-01 strongly affects the tumor microenvironment and that
stromal and tumor cells respond differently under disintegrin
exposure. These results contribute to the understanding of the
molecular mechanism of new anti-metastatic therapies targeting
integrin-mediated processes.
2DisBa-01: a recombinant RGD-disintegrin from Bothrops alter-
natus snake venom.
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